New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
05:11 EDTPRXL, SGYPSynergy Pharmaceuticals begins Phase IIb trial of Plescanatide in IBS-C
Synergy Pharmaceuticals (SGYP) announced that dosing has commenced in a Phase IIb clinical trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome, or IBS-C. This trial is being conducted at 70 sites in the U.S. and includes 350 patients with IBS-C who will be treated with one of four doses of plecanatide or placebo, taken once daily over a period of 12 weeks. PAREXEL International (PRXL) is the Contract Research Organization for the trial.
News For SGYP;PRXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
16:18 EDTPRXLPAREXEL sees Q3 EPS 62c-68c, consensus 69c
Subscribe for More Information
16:18 EDTPRXLPAREXEL sees FY15 EPS $2.65-$2.83 vs. previous $2.56-$2.75
Subscribe for More Information
16:17 EDTPRXLPAREXEL reports Q2 adjusted EPS 69c, consensus 60c
Subscribe for More Information
January 20, 2015
08:49 EDTPRXLPAREXEL downgraded to Neutral from Buy at SunTrust
SunTrust downgraded PAREXEL based on full valuation. Price target remains $65.
06:09 EDTPRXLPAREXEL downgraded to Neutral from Buy at SunTrust
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use